Eastman Chemical Company 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing is the Annual Report on Form 10-K for Eastman Chemical Company for the fiscal year ended December 31, 2024. Eastman is a global specialty materials company operating through four segments: Advanced Materials (AM), Additives & Functional Products (AFP), Chemical Intermediates (CI), and Fibers. The company focuses on an innovation-driven growth model, emphasizing sustainability and circular economy solutions, including the operation of one of the world's largest molecular recycling facilities.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Sales Revenue | $9.38 billion | $9.21 billion |
| Net Earnings (GAAP) | $905 million | $894 million |
| Diluted EPS (GAAP) | $7.67 | $7.49 |
| Adjusted Diluted EPS | $7.89 | $6.40 |
| EBIT (GAAP) | $1.28 billion | $1.30 billion |
| Adjusted EBIT | $1.30 billion | $1.10 billion |
| Operating Cash Flow | $1.29 billion | $1.37 billion |
| Total Borrowings | $5.02 billion | $4.85 billion |
| Cash and Equivalents | $837 million | $548 million |
| Capital Expenditures | $599 million | $828 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 2% year-over-year, driven by a 4% volume/mix increase partially offset by a 2% price decrease due to lower raw material costs.
- Profitability: While GAAP EBIT declined slightly (2%), Adjusted EBIT increased 18% to $1.30 billion, reflecting higher sales volume and lower raw material/energy costs net of price reductions.
- Segment Performance:
- Advanced Materials: Sales up 4%; Adjusted EBIT up 35% due to volume growth and capacity utilization.
- Additives & Functional Products: Sales up 1%; Adjusted EBIT up 12% driven by lower costs and volume growth in agriculture and personal care.
- Chemical Intermediates: Sales flat; Adjusted EBIT down 9% due to lower selling prices and higher raw material costs.
- Fibers: Sales up 2%; Adjusted EBIT up 8% driven by higher selling prices in acetate tow.
- Divestitures: The company completed the sale of its Texas City operations in late 2023, recognizing a $323 million gain in 2023. No comparable gain occurred in 2024.
Guidance, Outlook, and Risks
- Capital Allocation: Management prioritizes dividends, targeted growth opportunities, share repurchases, and bolt-on acquisitions. In 2024, the company repurchased $300 million of stock and declared a quarterly dividend of $0.83 per share.
- 2025 Outlook: Capital spending is expected to be between $700 million and $800 million, primarily for methanolysis plastic-to-plastic molecular recycling facilities and site modernization.
- Risks: Key risks include global economic uncertainty, volatility in raw material and energy costs, supply chain disruptions, and regulatory changes regarding environmental compliance and climate change. The company notes that inflationary pressures and interest rate fluctuations continue to impact operating costs and liquidity.
- Unusual Items: 2024 results included $51 million in asset impairments and restructuring charges, and a $54 million mark-to-market pension gain. 2023 included a significant $323 million gain on divestiture and $8 million in insurance proceeds from a steam line incident.
Investor Verification Checklist
- Adjusted EBIT Reconciliation: Verify the reconciliation of GAAP EBIT to Adjusted EBIT, specifically the $54 million pension gain and $51 million restructuring charges excluded in 2024.
- Segment Mix Shift: Confirm the impact of the 2023 product moves on segment comparability, particularly between Chemical Intermediates and Additives & Functional Products.
- Environmental Liabilities: Review Note 13 for the $252 million to $495 million range of estimated future environmental expenditures and the $284 million current reserve.
- Debt Maturity Profile: Assess the $5.02 billion total borrowings, noting the repayment of the 2024 Term Loan and the extension of the Credit Facility to 2029.
- Goodwill Impairment: Review the qualitative and quantitative goodwill impairment testing performed in Q4 2024, which resulted in no impairment charges despite market volatility.